Preparation, characterization, pharmacokinetics and ulcerative colitis treatment of hyperoside-loaded mixed micelles
© 2023. Controlled Release Society..
At present, ulcerative colitis (UC) has become a global disease due to its high incidence. Hyperoside (HYP) is a naturally occurring flavonoid compound with many pharmacological effects. This study aimed to develop HYP-loaded mixed micelles (HYP-M) to improve oral bioavailability of HYP and to evaluate its therapeutic effect on UC. The prepared HYP-M exhibited stable physical and chemical properties, smaller particle size (PS) (21.48 ± 1.37 nm), good polydispersity index (PDI = 0.178 ± 0.013), negative Zeta potential (ZP) (- 20.00 ± 0.48 mV) and high entrapment rate (EE) (89.59 ± 2.03%). In vitro release and in vivo pharmacokinetic results showed that HYP-M significantly increased the releasing rate of HYP, wherein its oral bioavailability was 4.15 times higher than that of free HYP. In addition, HYP-M was more effective in the treatment of UC than free HYP. In conclusion, HYP-M could serve as a novel approach to improve bioavailability and increase anti-UC activity of HYP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Drug delivery and translational research - 14(2024), 5 vom: 30. Apr., Seite 1370-1388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jin, Xingcheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8O1CR18L82 |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s13346-023-01470-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364491175 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364491175 | ||
| 003 | DE-627 | ||
| 005 | 20240403235031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13346-023-01470-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM364491175 | ||
| 035 | |a (NLM)37957475 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jin, Xingcheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation, characterization, pharmacokinetics and ulcerative colitis treatment of hyperoside-loaded mixed micelles |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Controlled Release Society. | ||
| 520 | |a At present, ulcerative colitis (UC) has become a global disease due to its high incidence. Hyperoside (HYP) is a naturally occurring flavonoid compound with many pharmacological effects. This study aimed to develop HYP-loaded mixed micelles (HYP-M) to improve oral bioavailability of HYP and to evaluate its therapeutic effect on UC. The prepared HYP-M exhibited stable physical and chemical properties, smaller particle size (PS) (21.48 ± 1.37 nm), good polydispersity index (PDI = 0.178 ± 0.013), negative Zeta potential (ZP) (- 20.00 ± 0.48 mV) and high entrapment rate (EE) (89.59 ± 2.03%). In vitro release and in vivo pharmacokinetic results showed that HYP-M significantly increased the releasing rate of HYP, wherein its oral bioavailability was 4.15 times higher than that of free HYP. In addition, HYP-M was more effective in the treatment of UC than free HYP. In conclusion, HYP-M could serve as a novel approach to improve bioavailability and increase anti-UC activity of HYP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hyperoside | |
| 650 | 4 | |a Micelles | |
| 650 | 4 | |a Oral bioavailability | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a Micelles |2 NLM | |
| 650 | 7 | |a hyperoside |2 NLM | |
| 650 | 7 | |a 8O1CR18L82 |2 NLM | |
| 650 | 7 | |a Quercetin |2 NLM | |
| 650 | 7 | |a 9IKM0I5T1E |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Xia, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaying |e verfasserin |4 aut | |
| 700 | 1 | |a Adu-Frimpong, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qilong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Huaxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Qingtong |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Toreniyazov, Elmurat |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jiangnan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ximing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug delivery and translational research |d 2011 |g 14(2024), 5 vom: 30. Apr., Seite 1370-1388 |w (DE-627)NLM207177104 |x 2190-3948 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:5 |g day:30 |g month:04 |g pages:1370-1388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13346-023-01470-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 5 |b 30 |c 04 |h 1370-1388 | ||